Difference between revisions of "Octreotide LAR (Sandostatin LAR)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| (12 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Long-acting dosage form of [[Octreotide (Sandostatin)]]. The LAR depot formulation consists of octreotide contained within biodegradable glucose star polymer microspheres; octreotide is gradually released as the polymer degrades via hydrolysis. [[Octreotide (Sandostatin)]] is a long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf Octreotide LAR (Sandostatin LAR) package insert]</ref><ref>[[ | + | Class/mechanism: Long-acting dosage form of [[Octreotide (Sandostatin)]]. The LAR depot formulation consists of octreotide contained within biodegradable glucose star polymer microspheres; octreotide is gradually released as the polymer degrades via hydrolysis. [[Octreotide (Sandostatin)]] is a long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf Octreotide LAR (Sandostatin LAR) package insert]</ref><ref>[[:File:Octreotideinjectablesuspension.pdf | Octreotide LAR (Sandostatin LAR) package insert (locally hosted backup)]]</ref><ref>[http://www.sandostatin.com Sandostatin LAR manufacturer's website]</ref> |
<br>Route: IM | <br>Route: IM | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Neuroendocrine | + | *[[Neuroendocrine tumor]] |
| + | *[[Pancreatic NET]] | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2011-11-25: New additional indication and a new dosage for the treatment of gastrointestinal [[neuroendocrine tumor]]. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/druginfo/Octreotide.aspx Octreotide (Sandostatin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Octreotide.aspx Octreotide (Sandostatin) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]</ref> | ||
| Line 20: | Line 23: | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intramuscular medications]] | [[Category:Intramuscular medications]] | ||
| − | |||
[[Category:Somatostatin analogs]] | [[Category:Somatostatin analogs]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
| + | [[Category:Pancreatic NET medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1998]] |
Latest revision as of 23:59, 2 September 2023
General information
Class/mechanism: Long-acting dosage form of Octreotide (Sandostatin). The LAR depot formulation consists of octreotide contained within biodegradable glucose star polymer microspheres; octreotide is gradually released as the polymer degrades via hydrolysis. Octreotide (Sandostatin) is a long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2][3]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in PMDA indication
- 2011-11-25: New additional indication and a new dosage for the treatment of gastrointestinal neuroendocrine tumor.
Patient drug information
- Octreotide (Sandostatin) patient drug information (Chemocare)[4]
- Octreotide (Sandostatin) patient drug information (UpToDate)[5]
Also known as
- Generic names: octreotide acetate for injectable suspension, octreotide long-acting release
- Brand names: Longastatina LAR, Sandostatin LAR, Sandostatin LAR Depot, Sandostatina LAR, Sandostatine LAR